Filtered by category: YASOPRS AWARDS Clear Filter

Friday Jerry Popham 2023 Bart Frueh Award Winner...What it means to me

The Friday Jerry Popham, MD winner was Benyam Kinde, MD, PhD for his “DNA Damage Checkpoint Kinases and Traumatic Optic Neuropathy” presentation.

To be selected for the Bart Frueh Award from a cohort of outstanding projects is a humbling experience. The groundbreaking research presented at the Fall 2023 meeting is inspiring, and I feel deeply honored to be a part of ASOPRS and to be selected for this award. This award underscores the shared commitment to advancing our understanding of complex conditions, such as traumatic optic neuropathy, and seeking innovative solutions to improve patient outcomes.

Read More

Thursday Bart Frueh Winner...What it Means to Me


Read More

Meet the 2023 Dale Meyer Rising Star

2023 Dale Meyer Rising Star, in my own words. 

                When I started my ophthalmology residency, I didn’t know much about the field of oculoplastic surgery. Working with Dr. David Tse in the clinic and operating room opened my eyes to a unique side of ophthalmology. I found myself drawn to complex cases requiring multidisciplinary care, and I felt inspired by the life-saving care we often provided. I was fortunate to care for a patient with lacrimal gland adenoid cystic carcinoma (LGACC) who had received trimodal therapy. This inspired my research into obtaining intraoperative margin clearance in tumor removal, which remains the highest risk factor for mortality.

Read More

Bart Frueh Award Winner -  Dr. Michelle Ting

"A Comparison of Proptosis Reduction with Teprotumumab vs. Surgical Decompression Based fat-to-muscle Ratio in Thyroid Eye Disease." 
Michelle Tang, MD

Dr. Michelle Ting graduated this year from the international ASOPRS fellowship at UCSD. While at UCSD, she was under the excellent tutelage and mentorship of Dr. Don Kikkawa, Dr. Bobby Korn, and Dr. Catherine Liu. Before her fellowship, she trained in the United Kingdom; she attended college and medical school at Cambridge University and Imperial College London, then undertook her residency at Moorfields Eye Hospital, including a year as Chief Resident. Now she enjoys working as an attending oculoplastic surgeon at the Royal Free Hospital in London, applying the skills and techniques she learned during fellowship and sharing ideas from across the pond with her residents and fellow.

We asked Dr. Ting to tell us about what inspired her and why she chose the topic that won her this year’s Bart Frueh Award.  

 “This year at the ASOPRS Fall Symposium, I was given the opportunity to present an exciting study that we conducted during my ASOPRS fellowship, “A comparison of proptosis reduction with teprotumumab versus surgical decompression based on the fat-to-muscle ratio in thyroid eye disease.” We chose to investigate this because teprotumumab is a new tool in our armamentarium of treatments for thyroid eye disease, but we had little idea of how it compared to the traditional treatment for proptosis, namely surgical decompression. Our idea was sparked by the clinical observation that not all patients were experiencing the same degree of response to teprotumumab, with some still going on to need surgical decompression but others responding very well to a course of the medicine alone. The idea for our study was also influenced by the findings of our previous work (for which we were also lucky to win the Bartley Frueh award in 2021!), “Differential effects of teprotumumab treatment based on the fat-to-muscle ratio in patients with thyroid eye disease” (Orbit 2002 Sep 12;1-8). We showed that the orbital fat-to-muscle ratio (FMR) in thyroid eye disease correlates with proptosis reduction in response to teprotumumab. Based on this, we wanted to explore whether FMR could be used to identify if surgical decompression or teprotumumab might lead to a greater reduction in proptosis. We looked at patients who had completed a course of teprotumumab and compared their level of proptosis reduction with patients who had undergone surgical decompression alone. We then stratified the patients into two groups, those with high FMR and those with low FMR, and found an interesting difference between the two. Patients with low FMR had similar levels of proptosis reduction with teprotumumab as compared to surgical decompression, but in patients with high FMR, orbital decompression was associated with a greater level of reduction in proptosis than teprotumumab. We concluded that FMR is a useful tool in predicting whether a patient will respond better to teprotumumab or surgery and that surgical decompression should still be considered as first-line treatment for patients with a high FMR. We hope our study helps to inform clinicians about how to counsel patients on the choice between teprotumumab and surgical decompression and to build a picture of where teprotumumab falls in the framework of treatments for thyroid eye disease.”

Bart Frueh Award Winner - Dr. Edith Reshef

Meet Edith Reshef, MD - 2022 Bart Frueh Award Winner for her presentation entitled Reduction in Extraocular Muscle Cross-sectional Area Following Teprotumumab for Thyroid Eye Disease.” 

Dr. Reshef attended the Massachusetts Institute of Technology before receiving her medical degree from Rutgers-Robert Wood Johnson Medical School. She completed her ophthalmology residency at the Massachusetts Eye and Ear/Harvard Medical School, where she subsequently completed an ASOPRS fellowship in Orbit and Oculofacial Plastic and Reconstructive surgery. She received a Heed Fellowship Award from the Society of Heed Fellows during her fellowship training. Dr. Reshef is joining the Boston Children’s Hospital/Harvard Medical School faculty to develop a pediatric oculoplastic surgery program.

Read More